RT Journal Article
SR Electronic
T1 Therapeutic Strategies for Targeting the IL-6/STAT3 Cytokine Signaling Pathway in Inflammatory Bowel Disease
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3749
OP 3756
VO 27
IS 6A
A1 KEIICHI MITSUYAMA
A1 SATOSHI MATSUMOTO
A1 JUNYA MASUDA
A1 HIROSHI YAMASAKI
A1 KOTARO KUWAKI
A1 HIDETOSHI TAKEDATSU
A1 MICHIO SATA
YR 2007
UL http://ar.iiarjournals.org/content/27/6A/3749.abstract
AB Interleukin-6 (IL-6) is a pleiotropic cytokine with central roles in immune and inflammatory reactions. IL-6 first binds to the IL-6 receptor (IL-6R), this complex then associates with gp130, inducing dimerization and the initiation of signaling through signal transducer and activator of transcription-3 (STAT3). Notably, the combination of soluble IL-6 receptor (sIL-6R) and IL-6 stimulates cells that only express gp130 and not IL-6R, a process known as trans-signaling. In contrast, soluble gp130 (sgp130) serves as a natural inhibitor of trans-signaling. Accumulated evidence strongly supports the hypothesis that the development and perpetuation of inflammatory bowel disease (IBD) relies on IL-6-mediated STAT3 activation on mucosal T-cells. This review looks at therapeutic strategies targeting the IL-6/STAT3 pathway in patients with IBD, including strategies involving the anti-IL-6 receptor antibody and soluble gp130Fc. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved